Dose Insider / Glossary / SELECT

SELECTThe heart trial of semaglutide in people without diabetes

Updated November 20, 2026 路 3 min read 路 Lincoff et al., N Engl J Med 2023; WEGOVY label

SELECT is the trial that showed semaglutide lowers heart risk in people with excess weight who do not have diabetes.

6.5%Semaglutide 2.4 mg, heart attack, stroke, CV death
Heart attack, stroke, CV deathSELECT, about 3.3 years, % of patientsSemaglutide 2.4 mg6.5%Placebo8.0%Heart attack, stroke, CVdeathSELECT, about 3.3 years, % of patientsSemaglutide 2.4 mg6.5%Placebo8.0%

Hazard ratio 0.80: about a fifth lower risk.

On this page

It enrolled 17,604 adults aged 45 or older with established cardiovascular disease and a body mass index of 27 or more, and gave them semaglutide 2.4 mg, the Wegovy dose, or placebo once a week. A first heart attack, stroke or cardiovascular death occurred in 6.5% on semaglutide against 8.0% on placebo. It was published in the New England Journal of Medicine in 2023.1

How the trial was run

SELECT was double-blind, randomized and event-driven: it was designed to run until enough heart events had occurred to answer its question. Participants had a history of cardiovascular disease, such as a past heart attack or stroke, and no history of diabetes. They were assigned in equal numbers, 8,803 to semaglutide and 8,801 to placebo, on top of their usual care.1

The main outcome was the first of three events: death from cardiovascular causes, a non-fatal heart attack or a non-fatal stroke. The dose was raised to 2.4 mg over a 16-week climb, and people who could not tolerate the full dose were allowed to stay at a lower one, as the Wegovy label notes.2 People took the trial drug for an average of 34.2 months and were followed for an average of 39.8 months, about 3.3 years.1

What it found

Lincoff et al., 2023; WEGOVY label, Table 6.1,2

Based on this trial, the Wegovy injection is approved to reduce the risk of major cardiovascular events in adults with established cardiovascular disease and either obesity or overweight.2 Earlier heart benefits of semaglutide had been shown in people with type 2 diabetes, in the Ozempic trial SUSTAIN 6; SELECT extended the finding to people without diabetes.3

Side effects and stopping

Adverse events led 16.6% on semaglutide to stop the drug for good, against 8.2% on placebo.1 That is a higher share than in the shorter weight trials, partly because people were followed for more than three years. Across the Wegovy weight trials, nausea was reported by 44% on the drug against 16% on placebo.2 Our page on nausea on a GLP-1 covers what helps.

How to read the result

A fifth lower risk is a relative figure. In absolute terms, about 1.5 fewer people in every 100 had a major heart event over roughly three years: 6.5 against 8.0. Put another way, about 67 people would need to take semaglutide for that period for one fewer event, an approximate figure we calculated from the published percentages. The trial did not separate how much of the benefit came from weight loss and how much from other effects of the drug.

Limits

SELECT enrolled only people who already had cardiovascular disease, so it does not show whether semaglutide prevents a first heart attack in people without it. It excluded people with diabetes, who were studied in other heart trials of GLP-1 medicines. The trial was funded by Novo Nordisk, the maker of semaglutide.1 Our page on Ozempic and Wegovy sets out which brand is approved for what.

Sources

  1. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med 2023;389:2221-2232. Funded by Novo Nordisk; NCT03574597. doi:10.1056/NEJMoa2307563
  2. WEGOVY (semaglutide) prescribing information, NDA 215256/S-025, revised June 2026. U.S. Food and Drug Administration; sections 1, 6.1 and 14.1. accessdata.fda.gov
  3. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). N Engl J Med 2016;375:1834-1844. doi:10.1056/NEJMoa1607141

Related analyses

Log your doses, weight and blood pressure and see them together.

Open Dose Insider